Google
BEAM — BEAM THERAPEUTICS INC (Healthcare >> Biotechnology)
BEAM FAQ
What is BEAM's P/E ratio?
BEAM THERAPEUTICS INC (BEAM) currently trades at a P/E ratio of 12.49.
What is BEAM's ROE?
BEAM THERAPEUTICS INC reports a Return on Equity (ROE) of -5.59%.
What is BEAM's dividend yield?
BEAM THERAPEUTICS INC offers a dividend yield of 0.00%.
What is BEAM's Deepscope Quality Score?
Deepscope rates BEAM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BEAM?
Deepscope's AI Timing Score for BEAM is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BEAM belong to?
BEAM THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 29.40
Price
-3.44
(-10.48%)
Day Change
|
|
|---|
BEAM, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 29.40 |
| PBV / Sector |
2.62 / 4.63
|
| Earning Per Share | -0.63 |
| PE / Sector |
12.49 / 17.43
GOOD
|
| PEG or PE/Growth / Sector |
1.46 / 0.53
|
| Average 1M Daily Value |
60.63 M
|
| Average 1W Daily Value |
69.24 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | BEAM |
| Name | BEAM THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 102.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,052.43 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 238 Main Street, Cambridge, MA, United States, 02142
Phone: 857 327 8775
Website: https://beamtx.com
Employees: 522
Sector: Healthcare >> Biotechnology
Description: Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
